LymphomaArchives
Clinical heterogeneity of primary cutaneous ?? T-cell lymphoma: a 20-year single-institution experience
Lymphoma 1 min.
Primary cutaneous γδ T-cell lymphoma (PCGDTCL) is a rare cutaneous T-cell lymphoma defined by γδ T-cell receptor expression and a cytotoxic phenotype. It has historically been considered highly aggressive, with median survival of 15-30 months and no standardized treatment due...
The impact of radiotherapy on the therapeutic response of patients treated with CAR T-cell therapy for high-grade lymphoma: a systematic review
Lymphoma 1 min.
Chimeric antigen receptor T (CAR -T) cell therapy is a promising form of cancer treatment with proven efficacy in relapsed/refractory lymphomas. However, there are limitations, including toxicity, failure to achieve immunological memory, and immune evasion. The rationale for administering radiotherapy...
TP53 mutations and baseline lymphocytes indicate response to glofitamab in relapsed or refractory diffuse large B-cell lymphoma
Lymphoma 1 min.
Although CAR-T cell therapy has emerged as a promising therapeutic option for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), long manufacturing time, high cost and toxicities limit its clinical use. T-cell engagers (TCEs) including glofitamab may address these unmet needs, but real-world...
Psychometric analysis of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library
Lymphoma 1 min.
Three patient-reported outcome (PRO) measures specific to lymphoma symptoms were previously defined using mixed-methods research, comprising questions from the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 items (QLQ-C30) and Item Library (IL):...
